Trying to get clarity on CDF and VPAS and implications for the IMF
pharmaphorum
OCTOBER 24, 2022
Companies who are thinking about seeking funding via England’s new Innovative Medicines Fund (IMF) need to think through all the commercial implications, including whether spending in the IMF counts towards rebates made against sales through the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).
Let's personalize your content